Clinical trial
COCCIMETRICS: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Measures for Endpoint Derivation in Patients With Progressive or Refractory Disseminated Coccidioidomycosis (DCM) Treated With Olorofim Plus Baseline Standard of Care (SOC) or With Placebo Plus Baseline SOC
NCT07712484 is registered in ClinicalTrials.gov with F2G Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- COCCIMETRICS: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Measures for Endpoint Derivation in Patients With Progressive or Refractory Disseminated Coccidioidomycosis (DCM) Treated With Olorofim Plus Baseline Standard of Care (SOC) or With Placebo Plus Baseline SOC
- Lead sponsor
- F2G Ltd
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- December 31, 2026
- Completion date
- July 31, 2028
- Enrollment
- 50 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
coccidioides immitis infection, coccidioides infection, coccidioides posadasii infection, coccidioidomycosis, coccidioidomycosis infection, disseminated fungal infection, san joaquin valley fever, valley fever